• B Bourrion, A Hazard, H Baltazard, P Sebbag, L Fournier, and M François.
• Département de médecine générale, faculté des sciences de la santé Simone-Veille, université Versailles-Saint-Quentin-en-Yvelines, 78180, Montigny le Bretonneux, France; Université Paris Saclay, Inserm, centre de recherche en épidémiologie et santé des populations, UMR1018, hôpital Pau-Brousse, bat 15-16, 16, avenue Paul-Vaillant Couturier, 94807 Villejuif cedex, France. Electronic address: bastienbou@hotmail.com.
• Rev Med Interne. 2020 Feb 1; 41 (2): 89-97.

IntroductionArterial obstructive disease is a disease affecting 11 % of the general population. This prevalence is constantly increasing. Nafronyl is still prescribed despite a decreasing reimbursement rate since 2005. The objective of this study was to summarize data from the scientific literature on the efficacy and safety of nafronyl used for the treatment of peripheral arterial obstructive disease.MethodA systematic review was made on EMBASE, MEDLINE and the Cochrane Library. Randomized controlled trials, systematic reviews and meta-analyses comparing naftidrofuryl with placebo were included. The main outcome was an improvement in the maximum walking distance or pain free walking distance. The quality of the reviews was analysed using a standardised reading grid. Only the best study was retained.ResultsAmong 193articles, one meta-analyses were selected. Naftidrofuryl improved the initial pain free walking distance by 60 % at six months, without a demonstrated increase in the risk of adverse reactions.ConclusionThe efficacy of naftidrofuryl over the maximum walking distance in peripheral arterial obstructive disease appears similar to physical exercise or simvastatin.Copyright © 2019 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

19 keywords...

hide…